濮阳东方上班时间濮阳东方医院男科技术很好,濮阳东方医院妇科做人流评价很不错,濮阳东方妇科医院做人流咨询,濮阳东方男科价格偏低,濮阳东方医院治疗阳痿价格,濮阳东方医院做人流专业吗,濮阳东方妇科医院做人流口碑很好放心

BERLIN, June 14 (Xinhua) -- A two-year-old boy became the first child to be killed by the deadly E. coli in Germany on Tuesday, officials said.To date, the terrifying EHEC infection has claimed 36 lives in Germany and one in Sweden.The child, from the northern town of Celle, died in hospital in Hanover of kidney failure and abnormal breakdown of red blood cells, two extreme symptoms of the infection with enterohaemorrhagic E. coli (EHEC), authorities in the state of Lower Saxony said.The boy became the youngest known fatal victim since the outbreak of E. coli in May. His father and 10-year-old brother were also infected with the deadly bacteria, but are recovering, doctors told a local newspaper.The Robert Koch Institute, Germany's national disease prevention and control agency, said on Tuesday that a total of 3, 235 cases had been reported in the country. Among them, 782 people are suffering from haemolytic uraemic syndrome (HUS), a life- threatening illness arising from E. coli, which would destroy human kidney and nervous system.The institute added that the number of new infections is declining sharply in recent days, with only seven reported on Tuesday.German authorities announced on Friday that bean sprouts from a farm in northern Germany were one source of the outbreak, and dropped the previous warning against eating raw cucumbers, tomatoes and lettuce. However, the food panic has caused losses worth hundreds of millions of dollars for European farmers.

BEIJING, Aug. 5 (Xinhuanet) -- A study conducted by Israeli researchers at the Albert Einstein College of Medicine in New York shows that genes, rather than good eating and lifestyle habits, determine longevity, according to media reports Friday. "This study suggests that centenarians may possess additional longevity genes that help to buffer them against the harmful effects of an unhealthy lifestyle," said senior author Nir Barzilai, director of the Institute for Aging Research at Yeshiva University's Albert Einstein College of Medicine.The study involves 477 Ashkenazi Jews between the ages of 95 and 122, of whom 75 percent are women. According to the study, Ashkenazi Jews are chosen as subjects because they are more "genetically uniform than other populations, making it easier to spot gene differences that are present."The study also found that the long-lived Ashkenazi Jews drank slightly more and exercised less than their average counterparts. But Barzilai also warned: “Although this study demonstrates that centenarians can be obese, smoke and avoid exercise, those lifestyle habits are not good choices for most of us who do not have a family history of longevity.""We should watch our weight, avoid smoking and be sure to exercise, since these activities have been shown to have great health benefits for the general population, including a longer lifespan," He added.

BERLIN, Aug. 28 (Xinhua) -- Mercedes-Benz, the world leading luxury car producer, celebrates the 125th anniversary of its invention of automobile with what it claimed the largest gathering ever, at the former Tempelhof airport in Berlin on the weekend.The Mercedes-Benz Club and Mercedes-Benz enthusiasts greet visitors with some 1,800 well-assorted Mercedes-Benz-branded vehicles, ranging from vintage and classic passenger cars to a variety of historic commercial vehicles, on a vast open areas of 250,000 square metres of the abandoned Tempelhof airport, which was closed in 2008.It took Mr. Lauritzen and his wife two days' drive of their cherised wecker of Mercedes-Benz Cabriolet B. 320.W 142.-3,4l to reach here for taking part in the pageant."It is a long journey, but we are happy to be here to see more class cars and more friends with same interests," Mrs Lauritzen said.Owners take the opportunity to present their lovingly cared-for vehicles, which include a number of truly rare items of automotive history, to the Berlin public.The couple of Mr. Kerner drove their red Mercedes-Benz 170Dba, a made-in-1952 model with a range of special and unique designs which are very rarely seen now, over journey of 155 km from Bitterfeld to join in the gala."I'm fond of driving my classic car of Benz," said Mrs Kerner, despite it can run maximally at a speed of 50 to 80 km per hour, "but I truly enjoy the diesel engine sounds and the historic feeling it evokes."The legendary Silver Arrows, dating from the 1930s and 1950s, are also presented from the Mercedes-Benz Classic collection for demonstration drives."The brilliant history of the Silver Arrows will be brought to life with a demonstration of their impressive engine sound and incredible driving dynamics," said Michael Bock, head of Mercedes-Benz Classic and Director of Mercedes-Benz Museum GmbH."It is not often that these racing cars are driven in public, so this will be a true highlight of the program of events in Tempelhof."During the grand show, visitors are also accessible to first-hand experiences of the latest technologies applicable in the future for in passenger cars, commercial vehicles and racing cars."Some 125 years ago, Carl Benz submitted his patent application for the Benz Patent Motor Car to the Patent Office in Berlin", the organizer appealed to the visitors, saying now Mercedes-Benz is returning to Berlin to celebrate together with Berliners.

SAN FRANCISCO, Sept. 22 (Xinhua) -- Former eBay Chief Executive Officer and California governor candidate Meg Whitman on Thursday was named Hewlett-Packard's new CEO, replacing Leo Apotheker who served 11 months on the job."We are fortunate to have someone of Meg Whitman's caliber and experience step up to lead HP," said the California-based company in a statement."We are at a critical moment and we need renewed leadership to successfully implement our strategy and take advantage of the market opportunities ahead," said the troubled tech giant.It noted that the job of the HP CEO now requires additional attributes to successfully execute on the company's strategy, adding Whitman "has the right operational and communication skills and leadership abilities to deliver improved execution and financial performance.""I am honored and excited to lead HP. I believe HP matters -- it matters to Silicon Valley, California, the country and the world," said Whitman in a statement.Whitman, 55, joined the HP board in January and served as president and CEO of eBay from 1998 to 2008, when she led the company through its initial public offering and massive growth.During her last years at eBay, she is blamed for not being able to halt the sales slowdown and overpaying for the 2005 acquisition of Skype with 4.1 billion dollars. In 2009, Skype was sold by eBay at a valuation of 2.75 billion dollars.Whitman won the Republican nomination for governor of California in 2010. She lost the election to Gov. Jerry Brown after spending more than 140 million dollars of her own fortune on the campaign. EnditemHP said the appointments are effective immediately, following the decision that Apotheker stepped down as president and CEO and resigned as a director of the company.Multiple U.S. media reported on Wednesday that Apotheker was to be ousted, sending HP shares soaring on the market and in the after-hour trading.Apotheker, 58, was named HP CEO 11 months ago to replace Mark Hurd, who was ousted due to a scandal over a personal relationship with a company contractor and then became co-president of Oracle. Before HP, Apotheker had served as CEO of German software giant SAP for 10 months.On Aug. 18, Apotheker announced that HP will shut down its mobile business, spin off its core personal computer business and transfer into a cloud-based software and services provider for businesses including a 10.3 billion-dollar acquisition of British software company Autonomy.Shares of the company plunged 20 percent the following day, the worst one-day loss since Black Monday in 1987.On Sept. 30, 2010, the day before Apotheker's appointment as HP CEO, the tech giant's stock closed at 42.04 dollars. On Tuesday, the price closed at 22.47 dollars, a decrease of 46.6 percent in less than a year.On Monday, HP was reported to begin sending over 500 employees pink slips in the WebOS division, after announcing to stop making WebOS devices in August.

LOS ANGELES, June 5 (Xinhua) -- U.S. researchers have developed two new drugs that can prolong the lives of patients with advanced melanoma, it was announced on Sunday.Research on both drugs was presented at the on-going annual meeting of the American Society of Clinical Oncology in Chicago, according to HealthDay News.This is the first big news in years for treatment of melanoma, one of the deadliest forms of skin cancer and one that is notoriously difficult to treat, let alone cure, the report said.The first treatment, vemurafenib, inhibits a gene mutation harbored in half of all melanoma patients, but is not yet approved by the U.S. Food and Drug Administration.The other drug, Yervoy (ipilumumab), is an immune system therapy that won approval in March."The March FDA approval of ipilumumab (Yervoy) was the first new drug approval for melanoma in 13 years," said Tim Turnham, executive director of the Melanoma Research Foundation.The two drugs were developed by researchers at Memorial Sloan- Kettering Cancer Center in New York City, the report said."This is really a huge step toward personalized care in melanoma," Dr. Paul Chapman, lead author of the first study and the attending physician in the melanoma/sarcoma service at Memorial Sloan-Kettering, said in a statement. "This (vemurafenib) is the first successful melanoma treatment tailored to patients who carry a specific gene mutation in their tumor, and could eventually become one of only two drugs available that improves overall survival in advanced cancers.""Having two trials that show a benefit in survival in patients with melanoma, both of these in first-line settings -- we weren't here just a few years ago," said Dr. Stephen Hodi, director of the Melanoma Center at Dana Farber Cancer Institute in Boston. "These are huge, paradigm-shifting results for the field."In the vemurafenib trial, sponsored by the drug's makers, researchers randomly assigned 675 patients with advanced, inoperable melanoma to receive either the chemotherapy drug dacarbazine or vemurafenib. Vemurafenib targets the V600E mutation in the BRAF gene.At the three-month mark, patients taking vemurafenib were 63 percent less likely to die and 74 percent less likely to die or see their cancer return, compared to patients taking dacarbazine alone.Few patients had side effects in the vemurafenib group, although some did develop squamous cell carcinoma, a less dangerous form of skin cancer.This is the first drug that has been proven superior to chemotherapy in this group of hard-to-treat patients, the researchers said."There was such a substantial benefit that we recommended that patients cross over," Chapman said at a Sunday news briefing. "It' s unprecedented to report a trial this early. The median follow-up time was three months." Yet the differences between the two groups became evident almost immediately.Dr. Lynn Schuchter, co-moderator of the briefing and division chief of hematology-oncology at Abramson Cancer Center of the University of Pennsylvania in Philadelphia, said symptoms subsided in some patients almost immediately, enabling them to cut back on pain medication in just 72 hours."The median time to progression with dacarbazine was 1.6 months versus three months with vemurafenib, which is a huge difference," said Chapman.In the second study, about 500 patients were randomly picked to receive Yervoy plus dacarbazine or dacarbazine alone.Those taking both drugs lived a median of 11.2 months compared to 9.1 months for those taking dacarbazine alone. Time to recurrence of disease was about the same for both groups: 2.8 months and 2.6 months, respectively.Almost half of those taking the combination therapy were alive after one year, compared to 36.3 percent in the other group. After two years, the rates were 28.5 percent and 17.9 percent, respectively.By three years out, 20.8 percent of those in the combination group were alive compared with 12.2 percent of those taking chemotherapy alone.This is the first study to combine chemotherapy and immunotherapy both safely and effectively.A study to test vemurafenib in combination with Yervoy has already begun, according to HealthDay News.